Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Strong Buy on Target, Lowers Price Target to $185

Raymond James analyst Bobby Griffin maintains Target (NYSE:TGT) with a Strong Buy and lowers the price target from $200 to $185.
byBenzinga Newsdesk
November 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Raymond James analyst Bobby Griffin maintains Target (NYSE:TGT) with a Strong Buy and lowers the price target from $200 to $185.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

IN8bio Announces Clinical Update Demonstrating Continued Durable Complete Remission In 100% Of Evaluable Patients In Phase 1 Trial Of INB-100 In Leukemia Presented At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk
December 11, 5:06 PM
Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including

INAB